Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Correction to: Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Svensson EM, Yngman G, Denti P, McIlleron H, Kjellsson MC, Karlsson MO.

Clin Pharmacokinet. 2019 Nov 2. doi: 10.1007/s40262-019-00835-4. [Epub ahead of print]

PMID:
31677024
2.

Relating nicotine plasma concentration to momentary craving across four nicotine replacement therapy formulations.

Germovsek E, Hansson A, Kjellsson MC, Perez Ruixo JJ, Westin Å, Soons PA, Vermeulen A, Karlsson MO.

Clin Pharmacol Ther. 2019 Jul 29. doi: 10.1002/cpt.1595. [Epub ahead of print]

PMID:
31355455
3.

A Bounded Integer Model for Rating and Composite Scale Data.

Wellhagen GJ, Kjellsson MC, Karlsson MO.

AAPS J. 2019 Jun 6;21(4):74. doi: 10.1208/s12248-019-0343-9.

4.

Translation Between Two Models; Application with Integrated Glucose Homeostasis Models.

Ibrahim MMA, Largajolli A, Kjellsson MC, Karlsson MO.

Pharm Res. 2019 Apr 17;36(6):86. doi: 10.1007/s11095-019-2592-9.

PMID:
31001701
5.

The integrated glucose insulin minimal model: An improved version.

Ibrahim MMA, Largajolli A, Karlsson MO, Kjellsson MC.

Eur J Pharm Sci. 2019 Jun 15;134:7-19. doi: 10.1016/j.ejps.2019.04.010. Epub 2019 Apr 9.

PMID:
30978382
6.

Variability Attribution for Automated Model Building.

Ibrahim MMA, Nordgren R, Kjellsson MC, Karlsson MO.

AAPS J. 2019 Mar 8;21(3):37. doi: 10.1208/s12248-019-0310-5.

7.

Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment.

Ibrahim MMA, Ueckert S, Freiberga S, Kjellsson MC, Karlsson MO.

AAPS J. 2019 Feb 27;21(3):34. doi: 10.1208/s12248-019-0305-2.

8.

Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics.

Stage TB, Wellhagen G, Christensen MMH, Guiastrennec B, Brøsen K, Kjellsson MC.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):105-114. doi: 10.1111/bcpt.13139. Epub 2018 Oct 30.

PMID:
30267605
9.

Model-Based Residual Post-Processing for Residual Model Identification.

Ibrahim MMA, Nordgren R, Kjellsson MC, Karlsson MO.

AAPS J. 2018 Jul 2;20(5):81. doi: 10.1208/s12248-018-0240-7.

PMID:
29968184
10.

Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests.

Ibrahim MMA, Ghadzi SMS, Kjellsson MC, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):432-441. doi: 10.1002/psp4.12302. Epub 2018 May 6. Erratum in: CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):520.

11.

Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes.

Wellhagen GJ, Karlsson MO, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):331-341. doi: 10.1002/psp4.12290. Epub 2018 Mar 25.

12.

Semi-physiological model of postprandial triglyceride response in lean, obese and very obese individuals after a high-fat meal.

Leohr J, Heathman M, Kjellsson MC.

Diabetes Obes Metab. 2018 Mar;20(3):660-666. doi: 10.1111/dom.13138. Epub 2017 Dec 4.

PMID:
29072819
13.

Model-Based Interspecies Scaling of Glucose Homeostasis.

Alskär O, Karlsson MO, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):778-786. doi: 10.1002/psp4.12247. Epub 2017 Sep 28.

14.

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Svensson EM, Yngman G, Denti P, McIlleron H, Kjellsson MC, Karlsson MO.

Clin Pharmacokinet. 2018 May;57(5):591-599. doi: 10.1007/s40262-017-0577-6. Erratum in: Clin Pharmacokinet. 2019 Nov 2;:.

15.

Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis.

Sheikh Ghadzi SM, Karlsson MO, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):686-694. doi: 10.1002/psp4.12214. Epub 2017 Sep 25.

16.

Impact of demographics and disease progression on the relationship between glucose and HbA1c.

Claussen A, Møller JB, Kristensen NR, Klim S, Kjellsson MC, Ingwersen SH, Karlsson MO.

Eur J Pharm Sci. 2017 Jun 15;104:417-423. doi: 10.1016/j.ejps.2017.04.006. Epub 2017 Apr 13.

PMID:
28412484
17.

Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose.

Røge RM, Bagger JI, Alskär O, Kristensen NR, Klim S, Holst JJ, Ingwersen SH, Karlsson MO, Knop FK, Vilsbøll T, Kjellsson MC.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):290-297. doi: 10.1111/bcpt.12792. Epub 2017 Jul 30.

18.

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches.

Møller JB, Kristensen NR, Klim S, Karlsson MO, Ingwersen SH, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):388-9. doi: 10.1002/psp4.12080. No abstract available.

19.

Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment.

Parkinson J, Hamrén B, Kjellsson MC, Skrtic S.

Br J Clin Pharmacol. 2016 Dec;82(6):1613-1624. doi: 10.1111/bcp.13069. Epub 2016 Aug 16.

20.

Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats.

Choy S, de Winter W, Karlsson MO, Kjellsson MC.

AAPS J. 2016 Sep;18(5):1203-1212. doi: 10.1208/s12248-016-9931-0. Epub 2016 May 31.

PMID:
27245226
21.

Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes.

Nyman E, Rozendaal YJ, Helmlinger G, Hamrén B, Kjellsson MC, Strålfors P, van Riel NA, Gennemark P, Cedersund G.

Interface Focus. 2016 Apr 6;6(2):20150075. doi: 10.1098/rsfs.2015.0075. Review.

22.

Weight-HbA1c-insulin-glucose model for describing disease progression of type 2 diabetes.

Choy S, Kjellsson MC, Karlsson MO, de Winter W.

CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):11-9. doi: 10.1002/psp4.12051. Epub 2015 Dec 16.

23.

Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.

Vildhede A, Mateus A, Khan EK, Lai Y, Karlgren M, Artursson P, Kjellsson MC.

Drug Metab Dispos. 2016 Apr;44(4):505-16. doi: 10.1124/dmd.115.066746. Epub 2016 Feb 3.

PMID:
26842596
24.

Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it.

Karlsson M, Janzén DL, Durrieu L, Colman-Lerner A, Kjellsson MC, Cedersund G.

BMC Syst Biol. 2015 Sep 4;9:52. doi: 10.1186/s12918-015-0203-x.

25.

The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.

Røge RM, Klim S, Ingwersen SH, Kjellsson MC, Kristensen NR.

CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00011. doi: 10.1002/psp4.11. Epub 2014 Dec 30.

26.

Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes.

Alskär O, Bagger JI, Røge RM, Knop FK, Karlsson MO, Vilsbøll T, Kjellsson MC.

J Clin Pharmacol. 2016 Mar;56(3):340-8. doi: 10.1002/jcph.602. Epub 2015 Oct 12.

PMID:
26224050
27.

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches.

Møller JB, Kristensen NR, Klim S, Karlsson MO, Ingwersen SH, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2014 Jul 2;3:e122. doi: 10.1038/psp.2014.20. Erratum in: CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):388-9.

28.

Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart.

Røge RM, Klim S, Kristensen NR, Ingwersen SH, Kjellsson MC.

J Clin Pharmacol. 2014 Jul;54(7):809-17. doi: 10.1002/jcph.270. Epub 2014 Mar 11.

PMID:
24446385
29.

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments.

Møller JB, Overgaard RV, Kjellsson MC, Kristensen NR, Klim S, Ingwersen SH, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 Oct 30;2:e82. doi: 10.1038/psp.2013.58.

30.

A model-based approach to predict longitudinal HbA1c, using early phase glucose data from type 2 diabetes mellitus patients after anti-diabetic treatment.

Kjellsson MC, Cosson VF, Mazer NA, Frey N, Karlsson MO.

J Clin Pharmacol. 2013 Jun;53(6):589-600. doi: 10.1002/jcph.86. Epub 2013 Apr 22.

PMID:
23606523
31.

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.

Choy S, Hénin E, van der Walt JS, Kjellsson MC, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):1-10. doi: 10.1007/s10928-012-9281-1. Epub 2012 Nov 24.

PMID:
23179858
32.

Good penetration of moxifloxacin into human abscesses.

Sauermann R, Karch R, Kjellsson MC, Feurstein T, Püspök A, Langenberger H, Böhmdorfer M, Jäger W, Zeitlinger M.

Pharmacology. 2012;90(3-4):146-50. doi: 10.1159/000341550. Epub 2012 Aug 3.

PMID:
22868236
33.

Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus.

Sauermann R, Feurstein T, Karch R, Kjellsson MC, Jäger W, Böhmdorfer M, Püspök A, Langenberger H, Wild T, Winkler S, Zeitlinger M.

Eur J Clin Pharmacol. 2012 Oct;68(10):1419-23. doi: 10.1007/s00228-012-1270-1. Epub 2012 Mar 23.

PMID:
22441316
34.

Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE 3rd, Dartois V.

Antimicrob Agents Chemother. 2012 Jan;56(1):446-57. doi: 10.1128/AAC.05208-11. Epub 2011 Oct 10.

35.

Modeling sleep data for a new drug in development using markov mixed-effects models.

Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO.

Pharm Res. 2011 Oct;28(10):2610-27. doi: 10.1007/s11095-011-0490-x. Epub 2011 Jun 17.

PMID:
21681607
36.

The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Silber HE, Kjellsson MC, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):81-99. doi: 10.1007/s10928-009-9112-1. Epub 2009 Feb 14.

PMID:
19219538
37.

Evaluation of the nonparametric estimation method in NONMEM VI.

Savic RM, Kjellsson MC, Karlsson MO.

Eur J Pharm Sci. 2009 Apr 11;37(1):27-35. doi: 10.1016/j.ejps.2008.12.014. Epub 2008 Dec 30.

PMID:
19159684
38.

Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

Kjellsson MC, Zingmark PH, Jonsson EN, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):483-501. doi: 10.1007/s10928-008-9098-0. Epub 2008 Sep 23.

PMID:
18810610
39.
40.

Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.

Jönsson S, Kjellsson MC, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2004 Aug;31(4):299-320.

PMID:
15563005

Supplemental Content

Loading ...
Support Center